Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Offene Stellen Rund 3.300 Mitarbeitende setzen sich bei Novartis Österreich gemeinsam dafür ein, das Leben von Patientinnen und Patienten zu verlängern und zu verbessern. Willst du dabei sein? Dann ...

September 25, 2025 - Bank of America Merrill Lynch Global Healthcare Conference ...

Zaposlitev v Novartisu v Sloveniji V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni ...

Modern Slavery Statement 2024 - Australia, Canada, and United Kingdom (PDF 0.3 MB) Our statement under UK, Canadian and Australian legislation on our efforts to address modern slavery. Norwegian ...

Product portfolio At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these ...

Researchers in Biomedical Research work across several diseases areas to uncover insights into the origins and pathogenesis of disease to drive drug discovery and early development, while the ...

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult ...

Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been ...

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment. The primary ...